Bis(tert-butoxycarbonylmethyl)aminoacetic acid benzyl ester | 171557-57-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Bis(tert-butoxycarbonylmethyl)aminoacetic acid benzyl ester
• 英文别名: benzyl 2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]acetate
• CAS: 171557-57-6
• 化学式: C₂₁H₃₁NO₆
• 分子量: 393.48
• InChiKey: ZNSBYFAUQMROIY-UHFFFAOYSA-N

物化性质

• 沸点：
  464.2±45.0 °C(Predicted)
• 密度：
  1.109±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Bis(tert-butoxycarbonylmethyl)aminoacetic acid benzyl ester 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以97%的产率得到(双-叔丁氧基羰基甲基-氨基)-乙酸
  参考文献：
  名称：

  设计双核Ni（II）-亚氨基二乙酸（IDA）复合物，用于选择性识别和共价标记His标签融合蛋白

  摘要：

  用小分子探针进行选择性蛋白质标记是阐明活细胞条件下蛋白质功能的通用方法。在这封信中，我们报告了双核Ni（II）-亚氨基二乙酸（IDA）复合物的设计，该复合物用于选择性识别和共价标记His-tag融合蛋白。我们发现，Ni（II）–IDA配合物1 -2Ni（II）以很强的结合亲和力（K d  = 24 nM）与His6-tag（HHHHHH）结合，其值比H（-）高16倍。常规Ni（II）–NTA络合物（K d = 390 nM）。Ni（II）-IDA复合物的强结合亲和力已成功用于位于活细胞表面的His-tag融合GPCR（G蛋白偶联受体）的共价标记和荧光生物成像。

  DOI：

  10.1016/j.bmcl.2014.04.096
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 甘氨酸苄酯盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以100%的产率得到Bis(tert-butoxycarbonylmethyl)aminoacetic acid benzyl ester
  参考文献：
  名称：

  设计双核Ni（II）-亚氨基二乙酸（IDA）复合物，用于选择性识别和共价标记His标签融合蛋白

  摘要：

  用小分子探针进行选择性蛋白质标记是阐明活细胞条件下蛋白质功能的通用方法。在这封信中，我们报告了双核Ni（II）-亚氨基二乙酸（IDA）复合物的设计，该复合物用于选择性识别和共价标记His-tag融合蛋白。我们发现，Ni（II）–IDA配合物1 -2Ni（II）以很强的结合亲和力（K d  = 24 nM）与His6-tag（HHHHHH）结合，其值比H（-）高16倍。常规Ni（II）–NTA络合物（K d = 390 nM）。Ni（II）-IDA复合物的强结合亲和力已成功用于位于活细胞表面的His-tag融合GPCR（G蛋白偶联受体）的共价标记和荧光生物成像。

  DOI：

  10.1016/j.bmcl.2014.04.096

文献信息

• Peptides for Treatment of Obesity
  申请人：Conde-Frieboes Kilian Waldemar

  公开号：US20130012432A1

  公开（公告）日：2013-01-10

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其有效调节一个或多个黑色素皮质素受体类型，以及该类化合物在治疗中的应用，包括通过将该类化合物用于需要的患者进行治疗的方法，以及该类化合物在制造药物中的应用。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或症状方面具有特别的兴趣。
• A Luminescent Sensor for Tyrosine Phosphorylation
  作者：Matthew S. Tremblay、Minhee Lee、Dalibor Sames

  DOI：10.1021/ol701920x

  日期：2008.1.1

  We have developed a luminogenic probe for tyrosine phosphorylation based on a short peptide sequence containing an iminodiacetate moiety near the site of phosphorylation. In response to kinase activity, the probe provides a strong luminescence enhancement, resulting from the increased ability of the probe to bind and sensitize Tb3+ and Eu3+ ions upon phosphorylation.
• Stereocontrolled Synthesis of DTPA Analogs Branched in the Ethylene Unit
  作者：Christopher W. Grote、Dong Jin Kim、Henry Rapoport

  DOI：10.1021/jo00126a059

  日期：1995.10

  Stereochemically controlled synthesis of diethylenetriaminepentaacetic acid (DTPA) analogues substituted on the ethylene backbones with methyl groups, the chiral center a to the terminal nitrogen being derived from (S)- or (R)-alanine, has been achieved. The key intermediate (S)-propylenediaminetriacetic acid triester was synthesized via selective detosylation of the alkylation product derived from (S)-alanine and tert-butyl glycinate. Attaching the remaining modified alanine (or glycine) fragment through acyl coupling and then selective reduction of the amide followed by hydrolysis of the esters afforded the substituted DTPA analogues. Ester differentiation has been accomplished through alkylation rather than acylation of the (S)-propylenediaminetriacetic acid triester. A byproduct from this alkylation is the oxazoloisoindole formed by internal alkylation of the oxygen of the phthaloyl protecting group. Phthaloyl deprotection followed by dialkylation afforded the ester-differentiated (S,S)-dipropylenetriaminepentaacetic esters. The enantiomeric purity of the chiral intermediates (S)-alaninol and (S)-propylenediamines were determined by HPLC using epimeric standards.
• PEPTIDES FOR TREATMENT OF OBESITY
  申请人：Novo Nordisk A/S

  公开号：EP2370104A1

  公开（公告）日：2011-10-05
• [EN] PEPTIDES FOR TREATMENT OF OBESITY<br/>[FR] PEPTIDES POUR LE TRAITEMENT DE L'OBÉSITÉ
  申请人：NOVO NORDISK AS

  公开号：WO2010060901A1

  公开（公告）日：2010-06-03

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.